Sleep apnoea and chronic insomnia: two common disorders, one major burden
Explore the clinical overlap between sleep apnoea and chronic insomnia, and the cumulative burden these conditions place on patients. Dr Livingston will explore diagnosis, treatment pathways and practical strategies for managing both disorders with a personalised approach to care. He also looks at the role of QUVIVIQ®▼ (daridorexant) in the management of chronic insomnia in these patients.
This webinar will discuss QUVIVIQ (daridorexant), manufactured by Idorsia Pharmaceuticals.
1 CPD hour
Click here to view prescribing information and adverse event reporting information
QUVIVIQ (daridorexant) is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.1
1. QUVIVIQ Idorsia Pharmaceuticals Ltd, summary of product characteristics
This site is intended for healthcare professionals only. Are you a healthcare professional?
This site is intended for healthcare professionals only.
CancelAn error occurred trying to play the stream. Please reload the page and try again.
Close